I[NTRODUCTION]{.smallcaps} {#sec1-1}
==========================

Estrogen, a steroid hormone in the human body, plays an important role in many physiological processes,\[[@ref1]\] such as the maintenance of secondary sexual characteristics, the development of neurons, and bone homeostasis.\[[@ref2]\] Estrogen is critical to maintain bone and bone density.\[[@ref3]\] Estrogen deficiency often leads to the emergence of osteoporosis. In postmenopausal women, estrogen secretion is markedly reduced, as is bone mineral density, whereas the incidence of bone fractures is increased. This form of osteoporosis is called postmenopausal osteoporosis (PO).\[[@ref4]\] An imbalance of osteoblasts and osteoclasts in the bone causes osteoporosis.\[[@ref5]\] PO has become one of the most important diseases that affect elder women, as it entails huge financial burdens for individuals and society, and reduces the quality of life.

In 1988, Komm *et al*.\[[@ref6]\] found that estrogen receptors (ERs) are expressed in osteoblasts, suggesting that estrogen may have a regulatory role for osteoblasts. After the discovery of ERs on osteogenic precursors and bone cells, an increasing number of studies has shown that estrogen has a direct effect on osteogenesis, as well as an indirect effect that does not depend on ERs. Kousteni *et al*.\[[@ref7]\] have found that estrogen can inhibit osteoblast apoptosis and prolong osteoblast life, thereby increasing the osteogenic capacity of each osteoblast. The effect of estrogen is achieved by rapid activation of ER-mediated regulatory kinases.\[[@ref8]\] The lack of estrogen causes a marked increase in nuclear factor-kappaB (NF-κB) activity in osteoblasts.\[[@ref9]\] Estrogen deficiency leads to an imbalance in bone metabolism between bone formation and resorption, eventually leading to osteoporosis. As the mechanism is not yet clear, further studies on estrogen regulation of bone metabolism and its signaling pathways are required to achieve a better understanding.

MC3T3-E1 cells are a clonal preosteoblastic cell line derived from newborn mouse calvarias, which is utilized in many osteoblast studies.\[[@ref10]\]

M[ETHODS]{.smallcaps} {#sec1-2}
=====================

Cell culture {#sec2-1}
------------

The clonal murine preosteoblastic cell line MC3T3-E1 was used in this study. The cells were thawed from frozen stocks and cultured in 100-mm culture dishes in α-minimum essential medium supplemented with 10% (v/v) fetal bovine serum (Thermo Fisher Scientific, Waltham, MA, USA), 1% (w/v) antibiotics/antimycotics (the stock solution contained 100 U/ml penicillin G sodium, 100 μg/ml streptomycin sulfate, and 0.25 μg/ml amphotericin B, in saline), 1.0 mmol/L sodium pyruvate, 0.1 mmol/L nonessential amino acids, and 1.5 g/L sodium bicarbonate (Thermo Fisher Scientific) at 37°C in a humidified atmosphere containing 5% (v/v) CO~2~. After establishing cultures from frozen cells, we subcultured the cells several times. Confluent cells were detached using 0.25% trypsin in Mg^2+^- and Ca^2+^-free phosphate-buffered saline (PBS, Thermo Fisher Scientific) before use. For the treatment of MC3T3-E1 with E2, the cells were seeded in each well of a 24- or 6-well plate with 0.5 or 2.0 ml of culture medium. The cells were incubated in the presence of E2 at different concentrations (0.01, 0.1, 1, and 10 nmol/L), and each concentration of E2 was maintained for three days. A group that received dimethyl sulfoxide (DMSO) served as the control.

Cell proliferation assay {#sec2-2}
------------------------

Cell proliferation was analyzed using the Cell Counting kit 8 (Dojindo, Tokyo, Japan). MC3T3-E1 cells were detached and seeded into 96-well plates at a density of 3 × 10^3^ cells/well. After 24 h, cells were treated with E2 at various concentrations (0, 0.01, 0.1, 1, and 10 nmol/L) and they were then incubated for another 24 h. Cell proliferation was analyzed according to the manufacturer\'s instructions. The optical density of each group was measured at 450 nm using a BioTek Microplate reader.

Cell apoptosis assay {#sec2-3}
--------------------

Cell apoptosis of MC3T3-E1 cells was analyzed with the TUNEL Apoptosis Detection Kit (Beyotime, ShangHai, China). Briefly, the cells were collected two days after treatment with E2, washed with PBS, and suspended in 500 μl binding buffer. Then, the cells were stained for the detection of apoptosis, according to the manufacturer\'s instructions. The ratio of apoptotic cells was analyzed under an optical microscope by counting terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL, Beyotime) positive cells in six randomly selected areas.

Total mRNA extraction {#sec2-4}
---------------------

Total cell mRNA was extracted using TRIzol^®^ (Thermo Fisher Scientific), according to manufacturer instruction (Invitrogen, USA). Smart Spec Plus (Bio-Rad, Hercules, CA, USA) was used to measure the absorption at 260/280 nm to assess the quality and quantity of the collected RNA. Finally, the integrity of the extracted RNA was further assessed using 1.5% agarose gel electrophoresis. Subsequently, the RNA was transcribed to first strand cDNA using the First Strand cDNA Synthesis Kit (TAKARA, SHIGA-KEN, Japan) for gene expression analysis.

RNA sequencing library construction and sequencing {#sec2-5}
--------------------------------------------------

We used 20 μg of total RNA from the control group and the 10 nmol/L E2-treated group for the RNA sequencing (RNA-seq) library preparation. The collected mRNA was purified and concentrated using oligo (dT)-conjugated magnetic beads (Invitrogen) before library preparation. The purified mRNA was randomly cut into fragments with the fragmentation buffer. We used the mRNA as a template, with 6-base random primers (Random hexamers, Thermo Fisher Scientific), to synthesize the first strand of cDNA. We then added dNTPs, RNase H, and DNA polymerase I to the buffer, to synthesize the second strand of cDNA. Finally, we used AMPure^®^ XP beads (Beckman, CA, USA) to purify the synthesized cDNA. The purification of double-stranded cDNA was performed with end repair and A-tailing. The AMPure^®^ XP (Beckman) beads were used to select the size of the fragments. Finally, the cDNA library was obtained by PCR. Using "sequencing by synthesis" technology, we sequenced the cDNA libraries with the HiSeq2500 (Illumina, San Diego, CA 92122, USA) high-throughput sequencing platform and obtained high-quality reads. The reads and bases sequenced by the platform were usually considered raw data, and most of them got a Q30 score for base quality.

Analysis of differentially expressed genes {#sec2-6}
------------------------------------------

Gene expression has time- and space-specific characteristics, and both external stimulation and the internal environment can affect gene expression. Under two different conditions (such as the control and treatment, wild-type and mutant, different times, different organizations, *etc*.), genes that have significantly different expression are considered differentially expressed genes (DEGs). Similarly, transcripts with significantly different expression are called differentially expressed transcripts. In bioinformatics, the process of finding differentially expressed transcripts or DEGs is known as differential expression analysis.

Annotation and analysis of differentially expressed genes {#sec2-7}
---------------------------------------------------------

The gene ontology (GO) database was built in 2000 and is a standard, structured biological annotation system aimed at establishing a system of standard vocabulary and knowledge of genes and their products. The GO annotation system contains three main branches: biological process, molecular function, and cellular component. We used the GO database to predict the functions of the DEGs identified in this study.\[[@ref11]\] Enrichment analysis of the differences between samples was carried out using Top GO. Top GO directly displays the GO node and the hierarchical relationship of the DEGs. The clusters of orthologous groups (COG) of proteins database is constructed on the basis of the phylogeny of bacteria, algae, and eukaryotes to classify the orthologs of gene products. To annotate the pathways of the DEGs, it is necessary to analyze the functions of the genes. The Kyoto Encyclopedia of Genes and Genomes (KEGG) database is a major metabolic pathways database.\[[@ref12]\] The analysis of the overpresentation of the DEGs in a pathway is important to determine the functions of the genes. In our study, COG and KEGG were used to analyze the DEGs.

Quantitative real-time polymerase chain reaction validation {#sec2-8}
-----------------------------------------------------------

Total cell mRNA was extracted using TRIzol^®^, according to manufacturer instruction (Invitrogen). We subjected 10 μg of total RNA to DNaseI treatment with 1 U DNaseI (NEB, MA, USA). The reaction was carried out at 37°C for 10 min followed by heat inactivation at 65°C for 10 min. We then used 2.5 μg of DNase-treated RNA for cDNA synthesis with reverse transcriptase (Bio-Rad), in accordance with the manufacturer\'s protocol. The expression of the *Gapdh* gene, which the transcriptome database indicated was stable, was used as the control for quantitative real-time polymerase chain reaction (qRT-PCR) experiments. Primers were designed for selected transcripts from the transcriptome database, and real-time PCR was performed with SYBR^®^ Green I master mix (TAKARA) on a CFX Connect™ Real-Time PCR Detection System (Bio-Rad). The relative expression of the transcripts was calculated using the 2^ΔΔ^ CT method.

Estrogen receptor α and estrogen receptor β antagonist treatment of MC3T3-E1 cells {#sec2-9}
----------------------------------------------------------------------------------

For the ERα and ERβ antagonist experiments, the ERα antagonist 1,3-bis (4 hydroxyphenyl)-4-methyl-5-\[4- (2-piperidinylethoxy)phenol\]-1H-pyrazole dihydrochloride (MPP) and the ERβ antagonist 4-(2-phenyl-5,7-bis\[trifluoromethyl\] pyrazolo \[1,5-a\]pyrimidin-3-yl) (PTHPP) were added to the MC3T3-E1 cultures. After 72 h of treatment with the antagonists, the cells were harvested to quantify the target gene expression.

ChIP assays {#sec2-10}
-----------

ChIP assays were performed according to the manufacturer\'s protocol (ChIP Assay Kit, Millipore, MA, USA). Briefly, MC3T3-E1 cells were collected after culture with or without E2, cross-linked in 2% formaldehyde at 28°C for 30 min, then treated with a 1 / 10 volume of 1.25 mol/L glycine to stop cross-linking, followed by PBS washes (three washes for 10 min each). We used purified rabbit or mouse IgG (Invitrogen) as a negative control and an antibody against ERβ to pull down the DNA. We performed ChIP PCR using primers flanking the estrogen response element (ERE) sites, as well as primers not flanking the ERE sites in the promoter regions of *Tgfbr1* and *Bmpr1a* as controls.

Statistical analysis {#sec2-11}
--------------------

The statistical analyses were performed with JMP13.0 (SAS Institute Inc. Cary, NC, USA), and a *P* \< 0.05 was considered statistically significant. Data were presented as mean ± standard deviation (SD). Statistical differences between two groups were determined with Student\'s *t*-test. Statistical differences among groups were analyzed with a one-way analysis of variance (ANOVA) followed by Student\'s test. All experiments were repeated at least three times, and representative experiments were shown.

R[ESULTS]{.smallcaps} {#sec1-3}
=====================

E2 increased MC3T3-E1 cell proliferation and apoptosis {#sec2-12}
------------------------------------------------------

To check whether the estrogen effects the MC3T3-E1 cell\'s proliferation and apoptosis, different concentrations of estrogen (0, 0.01, 0.1, 1, and 10 nmol/L) were used to treat the MC3T3-E1 cells. CCK-8 and TUNEL experiments were performed. The results show MC3T3-E1 cell proliferation and apoptosis was not changed in the low concentration-treated groups (0.01 and 0.1 nmol/L estrogen-treated groups) compared with DMSO control groups. However, in the high-concentration estrogen groups (1 and 10 nmol/L estrogen-treated groups) the MC3T3-E1 cell apoptosis significantly increased compared with the DMSO control groups \[[Figure 1](#F1){ref-type="fig"}\]. The 10 nmol/L concentration is higher than the physiological concentration, for obtain the robust data, so we sampled the 10 nmol/L treated group to perform RNA-seq and explore the mechanisms of the estrogen effects on MC3T3-E1 cells.

![Effects of estrogen on MC3T3-E1 proliferation (a) and apoptosis (b). MC3T3-E1cells were treated with different concentrations of E2, then subjected to analysis with a CCK-8 assay (a) and the TUNEL Apoptosis Detection Kit (b). Student\'s *t*-test. \**P* \< 0.05; ^†^*P* \< 0.01.](CMJ-131-2558-g001){#F1}

RNA sequencing and identification of differentially expressed genes {#sec2-13}
-------------------------------------------------------------------

To assess the effects of E2 on gene transcription, we used the Cuffdiff analysis module Cufflinks to analyze the differential gene expression in the samples.\[[@ref13]\] The screening criteria for significant differences in the expression of genes are \|log2Ratio\| ≥1 and *q* ≤ 0.05. Using these criteria, we identified 460 DEGs. Among those DEGs, 66 genes were upregulated and 394 genes were downregulated in the cells treated with 10 nmol/L E2-treated group \[[Figure 2](#F2){ref-type="fig"}\].

![The RNA-seq identified DEGs. The screening criteria to identify significant differences in the expression of genes are \|log2Ratio\| ≥1 and *q* ≤ 0.05. RNA-seq: RNA sequencing; DEGs: Differentially expressed genes.](CMJ-131-2558-g002){#F2}

Gene ontology analysis and Kyoto encyclopedia of genes and genomes pathway functional analysis of enriched differentially expressed genes {#sec2-14}
-----------------------------------------------------------------------------------------------------------------------------------------

GO is an internationally standardized gene functional classification system that provides a set of dynamically updated vocabularies to comprehensively describe the properties of genes and gene products in organisms. The most enriched GO results for the three ontologies are shown in [Table 1](#T1){ref-type="table"}. We found that genes that affect biological regulation, metabolic processes, development, anatomical structure development, responses to stimulation, systems development, cell differentiation, cell communication, regulation of gene expression, and signal transduction were enriched in the DEGs \[[Table 2](#T2){ref-type="table"}\].

###### 

GO enriched by differentially expression genes

  GO ID        GO-term                            Hits   *t*     *P*
  ------------ ---------------------------------- ------ ------- ---------
  GO:0065007   Biological regulation              216    2.787   0.00455
  GO:0008152   Metabolic process                  180    3.098   0.00234
  GO:0032502   Developmental process              118    3.135   0.00265
  GO:0048856   Anatomical structure development   103    3.191   0.00012
  GO:0048731   System development                 83     3.113   0.00265
  GO:0050896   Response to stimulus               109    2.812   0.00326
  GO:0030154   Cell differentiation               73     3.206   0.00174
  GO:0007154   Cell communication                 73     2.744   0.00354
  GO:0010468   Regulation of gene expression      98     3.175   0.00104
  GO:0007165   Signal transduction                62     3.231   0.00278

GO: Gene ontology.

###### 

KEGG pathway enriched by differentially expression genes

  Pathway ID   Pathway                      Hits genes                                                               *P*       *t*
  ------------ ---------------------------- ------------------------------------------------------------------------ --------- -------
  ko05200      Pathways in cancer           *Kras, Cul2, Appl1, Chuk, Hif1a, Msh2, Mecom, Birc2, Ccna2, Fgf5, Fos*   0.00176   4.025
  ko04350      TGF-beta signaling pathway   *Sp1, Inhba, Tgfbr1a, Rbl1, Rock1, Sp1, Bmp1ra*                          0.00480   4.325
  ko04010      MAPK signaling pathway       *Kras, Chuk, Rasa1, Tgfbr1a, Mecom, Rasa2, Fgf5, Fos*                    0.01030   3.169
  ko04510      Focal adhesion               *Pdpk1, Vav3, Arhgap5, Birc2, Rock1, Actn2*                              0.01145   3.148
  ko04310      Wnt signaling pathway        *Lrp6, Vangl2, Rock1*                                                    0.01264   4.751
  ko04064      NF-κB signaling pathway      *Chuk, Birc2*                                                            0.01721   5.462
  ko04380      Osteoclast differentiation   *Chuk, Fos, Tgfbr1a*                                                     0.03135   3.198
  ko04810      Cell cycle                   *Atr, Smc1a, Rbl1, Ccna2, Stag1*                                         0.04867   2.765

KEGG: Kyoto encyclopedia of genes and genomes; TGF: Transforming growth factor; MAPK: Mitogen-activated protein kinase; NF-κB: Nuclear factor-kappaB.

Multiple genes coordinate their biological functions *in vivo*. Pathway-based analysis enables further understanding of the biological functions of the genes. KEGG is the main public pathway database. Because we focus on the bone metabolism process, so bone metabolisms pathway was come into our view. We found that the DEGs were enriched for genes involved in the pathways for cancer, mitogen-activated protein kinase (MAPK) signaling, transforming growth factor-beta (TGF-β) signaling, focal adhesion, Wnt signaling, NF-κB signaling, and osteoclast signaling \[[Table 2](#T2){ref-type="table"}\]. The TGF-β and Wnt signaling pathways are important in osteoblasts. Through the pathway maps, we identified alterations in the expression of *Bmpr1a*, *Tgfbr1*, *Rock1*, and s*p1*, which are involved in the TGF-β signaling pathway \[[Table 2](#T2){ref-type="table"}\]. We also noted alterations in the expression of *Lrp5*, *Vangl2*, and *Rock1*, which are involved in Wnt signaling \[[Table 2](#T2){ref-type="table"}\]. In the cell cycle signaling pathway, we noted alteration in the expression *Ccna2 Stag2*, *Atr*, *Smc1a* and *Rbl1*. These data show that the effects of estrogen maybe mediated via the TGF-β and Wnt signaling pathways in MC3T3-E1 cells.

Confirmation of differentially expressed genes expression by quantitative real-time polymerase chain reaction {#sec2-15}
-------------------------------------------------------------------------------------------------------------

We chose the candidate target genes from the bone metabolic signaling pathway. The candidate genes and their relative gene functions are listed in [Figure 3a](#F3){ref-type="fig"}. Among those genes, *Sp1*, *Tgfbr1*, and *Rock1* belong to the TGF-β signaling pathway; *Bmpr1a* belongs to the BMP signaling pathway; *Fos* is from the osteoclast differentiation pathway; *Lrp6 is* from the Wnt signaling pathway; and *Adra1b* belongs to the calcium signaling pathway. The qRT-PCR results indicated that *Bmpr1a*, *Tgfbr1*, *Rock1*, *Lrp6*, and *Sp1* were downregulated by E2 treatment whereas *Fos* and *Adra1b* were upregulated \[Figure [3b](#F3){ref-type="fig"}--[3h](#F3){ref-type="fig"}\]. These results confirmed the differential expression after E2 treatment of the genes identified by RNA-seq.

![Confirmation of the mRNA levels of the DEGs by qRT-PCR. We treated MC3T3-E1 cells with 10 nmol/L E2, then extracted total RNA for qRT-PCR. Three independent experiments were conducted. The candidate genes and their relative gene functions are listed (a). The qRT-PCR results indicated that *Bmpr1a* (b), *Tgfbr1* (c), *Rock1* (d), *Lrp6*, (f), and *Sp1* (h) were downregulated by E2 treatment, whereas *Fos* (e) and *Adra1b* (g) were upregulated. Student\'s *t*-test was performed. \**P* \< 0.05; ^†^*P* \< 0.01. DEGs: Differentially expressed genes; qRT-PCR: Quantitative real-time polymerase chain reaction.](CMJ-131-2558-g003){#F3}

Estrogen negatively regulated gene expression via estrogen receptor β {#sec2-16}
---------------------------------------------------------------------

Estrogen is an important endocrine regulator of bone metabolism, which mediates it effects via ERs.\[[@ref14]\] ERs are transcription factors that bind EREs to activate or repress target gene expression.\[[@ref15]\] Two mammalian ERs have been identified, ERα and ERβ.\[[@ref16]\] Previous studies revealed that estrogen represses *SOST* expression through ERβ.\[[@ref17]\] To investigate if the differential gene expression in the E2-treated MC3T3-E1cells was mediated through ERβ, we analyzed the *Bmpr1a* and *Tgfbr1* promoters using online bioinformatics software (<http://jaspar.binf.ku.dk/>). The results identified three EREs and two EREs in the *Bmpr1a* and *Tgfbr1* gene promoters, respectively \[[Figure 4a](#F4){ref-type="fig"}\]. To determine if E2 repressed the candidate genes via a particular ER, we treated MC3T3-E1cells with 10 nmol/L E2, then added the ERα antagonist MPP or the ERβ antagonist PTHPP. We then performed qRT-PCR to investigate candidate gene expression. We found that E2 treatment significantly downregulated *Bmpr1a* and *Tgfbr1*, compared to their expression in the DMSO control groups, in the MC3T3-E1 cells. MPP did not rescue the E2-mediated downregulation of *Bmpr1a* and *Tgfbr1*. However, PTHPP treatment rescued the downregulation of *Bmpr1a* and *Tgfbr1* \[Figure [4b](#F4){ref-type="fig"} and [4c](#F4){ref-type="fig"}\]. Rescue of the candidate target gene expression by PTHPP, but not MPP, revealed that estrogen negatively regulates gene expression via ERβ.

![Estrogen negatively regulated gene expression via ERβ. The promoter analysis of *Bmpr1a* and *Tgfbr1* (a). MC3T3-E1cells was treated with 10 nmol/L E2, and 0.1 μmol/L MPP or 0.1 μmol/L 4-(2-phenyl-5,7-bis\[trifluoromethyl\] pyrazolo\[1,5-a\]pyrimidin-3-yl), the candidate target mRNA level was quantified via qRT-PCR. The expression level of *Bmpr1a* under different treated (b). The expression level of *Tgfbr1* under different treated (c). Student\'s *t*-test was performed. \**P* \< 0.05; ^†^*P* \< 0.01. NS: No significant; qRT-PCR: Quantitative real-time-polymerase chain reaction; ER: Estrogen receptor.](CMJ-131-2558-g004){#F4}

E2 increased estrogen receptor β binding to the EREs of the *Bmpr1a* and *Tgfbr1* promoters in MC3T3-E1cells {#sec2-17}
------------------------------------------------------------------------------------------------------------

We next addressed the potential functionality of the EREs located in the *Bmpr1a* and *Tgfbr1* promoters. We performed ChIP experiments using an ERβ antibody to determine if ERβ bound to the EREs in the *Bmpr1a* and *Tgfbr1* promoters. We found that ERβ bound to ERE1 and ERE3, but not ERE2, in the *Bmpr1a* promoter \[[Figure 5a](#F5){ref-type="fig"}\]. Both of the EREs located in the *Tgfbr1* promoter were bound by ERβ [Figure 5b](#F5){ref-type="fig"}\]. To investigate if E2 treatment affected the binding of ERβ in the *Bmpr1a* and *Tgfbr1* promoters, we treated the MC3T3-E1 cells with E2 for 72 h, then performed ChIP, followed by qRT-PCR. E2 treatment increased ERβ binding to ERE1 and ERE3 in the *Bmpr1a* promoter \[[Figure 5c](#F5){ref-type="fig"}\] and ERE1 and ERE2 in the *Tgfbr1* promoter \[[Figure 5d](#F5){ref-type="fig"}\]. These data demonstrated that ERβ can bind to the *Bmpr1a* and *Tgfbr1* promoters and that E2 increased ERβ binding to the EREs of the *Bmpr1a* and *Tgfbr1* promoters in MC3T3-E1cells.

![E2 increased ERβ binding to the EREs located in the *Bmpr1a* and *Tgfbr1* promoters in MC3T3-E1cells. Ch-IP experiments were performed in the MC3T3-E1cells use ERβ antibody. ERβ binding to ERE1 and ERE3 not ERE2 located in *Bmpr1a* promoter (a). Both of the EREs located in the *Tgfbr1* promoter were bound by ERβ (b). MC3T3-E1 cells were treated with 10 nmol/L E2 for 72 h, then performed ChIP, followed by qRT-PCR. E2 treatment increased ERβ binding to ERE1 and ERE3 in the *Bmpr1a* promoter (c), and increased ERβ binding to ERE1 and ERE2 in the *Tgfbr1* promoter (d). Student\'s *t*-test was performed. \**P* \< 0.05; ^†^*P* \< 0.01; ^‡^*P* \< 0.001. qRT-PCR: Quantitative real-time polymerase chain reaction; ER: Estrogen receptor; ERE: Estrogen response element.](CMJ-131-2558-g005){#F5}

D[ISCUSSION]{.smallcaps} {#sec1-4}
========================

E2, a synthetic, exogenous estrogen that is functionally similar to endogenous estrogen, is commonly used to study the function of estrogen. MC3T3-E1 cells are a newborn mouse calvarias cell line, which is commonly used in the study of osteoblasts. ERα and ERβ have also been identified in this cell line, so MC3T3-E1 can be used to study the role of estrogen in the regulation of osteoblast function.

We found that estrogen increases the rates of proliferation and apoptosis in MC3T3-E1 cells. We used CCK-8 and TUNEL assays to investigate the proliferation and apoptosis of MC3T3-E1 cells after E2 treatment. We found no significant differences in the groups treated with low concentrations of E2 after three days. However, high concentrations of E2 promoted the proliferation and apoptosis of MC3T3-E1 cells. E2-mediated increases in the proliferation of MC3T3-E1 cells have been reported in the previous studies,\[[@ref18]\] but we also found a slight but statistically significant increase in the number of apoptotic cells in our high-concentration group, which indicated that treatment with E2 for three days was slightly toxic to MC3T3-E1 cells.

Estrogen affects many signaling pathways that are associated with bone metabolism. In both transcriptome libraries, these pathways can be identified by GO enrichment and KEGG pathway analysis of the DEGs. After E2 treatment of the MC3T3-E1 cells, cell differentiation- and cell cycle-related genes were significantly enriched among the DEGs. The involvement of these pathways can explain why E2-treated MC3T3-E1 cells undergo increased cell proliferation and apoptosis. KEGG signaling pathway analysis indicated that genes in the Wnt, MAPK, and calcium signaling pathways, and osteoclast differentiation genes were significantly enriched among the DEGs. The enrichment of genes in these bone metabolic pathways among the DEGs demonstrated osteoblast-like differentiation of the MC3T3-E1 cells.

However, in our sequencing results, in addition to these signaling pathways, we found that the TGF-β signaling pathway and cancer-related signaling pathways were also enriched, in contrast with the research of Zhen *et al*. The TGF-β signaling pathway plays an important role in bone differentiation, especially in osteogenesis.\[[@ref19]\] The TGF-β superfamily of ligands includes BMPs, growth and differentiation factors, anti-müllerian hormone, activin, nodal, and the TGF-β proteins.\[[@ref20]\] Signaling begins with the binding of a TGF-β superfamily ligand to a TGF-β type II receptor.\[[@ref21]\] The type II receptor is a serine/threonine receptor kinase, which catalyzes the phosphorylation of the type I receptor.\[[@ref20]\] Each class of ligand binds to a specific type II receptor. In mammals, there are seven known type I receptors and five type II receptors.\[[@ref20]\] In our sequencing results, we found that *Tgfbr1* and *Bmpr1a* levels were significantly reduced in MC3T3-E1 cells after E2 treatment, and qRT-PCR confirmed this result. *Tgfbr1* is also called activin receptor-like kinase receptor (*Alk5*),\[[@ref22]\] *ALK5* protein is strongly expressed in perichondrial progenitor cells for osteoblasts and in a thin chondrocyte layer located adjacent to the perichondrium in the peripheral cartilage.\[[@ref23]\] Conditional knockout of the TGF-β type I receptor Alk5 in skeletal progenitor cells resulted in growth plates that had an abnormally thin perichondrial cell layer, as well as reduced proliferation and differentiation of osteoblasts.\[[@ref24]\]

The BMP receptors are a family of transmembrane serine/threonine kinases that include the type I receptors *Bmpr1a* and *Bmpr1b*, and the type II receptor *Bmpr2*.\[[@ref20]\] Deletion of the receptor *Bmpr1a* in the osteoblast lineage cells with a *Dmp1*-Cre caused a dramatic increase in trabecular bone mass in postnatal mice, which was due to a marked increase in osteoblast numbers. Another study revealed that conditional deletion of *Bmpr1a* in differentiated osteoclasts negatively regulates osteoclast differentiation.\[[@ref25]\] However, osteoblast-specific deletion of *Bmpr1a* resulted in increased bone volume with marked decreases in bone formation rate (BFR) in tibias at 8 weeks of age.\[[@ref26]\] Thus, physiological *Bmpr1a* signaling in bone exerts a dual function in both restricting preosteoblast proliferation and promoting osteoblast activity. The impact of decreased *Tgfbr1* and *Bmpr1a* expression on MC3T3-E1 cell differentiation or increasing osteoclast activity must be further explored.

Estrogen inhibits the expression of *Tgfbr1* and *Bmpr1a* through ERβ. Previous studies have also shown that estrogen can inhibit the expression of *SOST* through ERβ.\[[@ref17]\] To confirm that estrogen inhibits the expression of *Tgfbr1* and *Bmpr1a* through ERβ, we used ERα- and ERβ-specific inhibitors and found that only the ERβ inhibitor rescued the expression of *Tgfbr1* and *Bmpr1a*. In addition, our ChIP experiment also demonstrated that ERβ binds to the *Tgfbr1* and *Bmpr1a* promoters. In mouse lung cancer tissue, estrogen was found to inhibit the expression of *Bmpr2* through ERα.\[[@ref27]\] Estrogen also inhibits the activity of the TGF-β signaling pathway by promoting Smad2/3 degradation.\[[@ref28]\] In another study, estrogen replacement decreases the accumulation of TGF-β1 on vascular smooth muscle cell (VSMC).\[[@ref29]\] In this study, we found that the ER signaling pathway and the TGF-β signaling pathway participate in crosstalk, and ERβ can inhibit *Tgfbr1*. Therefore, estrogen can downregulate the expression of *Tgfbr1* and *Bmpr1a* in MC3T3-E1 cells.

In conclusion, Estrogen can affect bone metabolism through several bone metabolism-related signaling pathways. In MC3T3-E1 cells, estrogen appears to affect bone by negatively regulating *Tgfbr1* and *Bmpr1a* expression. Our research provides a new understanding of the mechanism by which estrogen acts on osteoblasts.
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